News about the DiaPat-CoV-50 test for the prognostic detection of the severe Covid-19 course from day "0" of the PCR determination
by Petra Zürbig
The results of the Crit-CoV-U study with 1,017 patients are available and confirm the results of the interim report that led to the special approval by the German Federal Institute for Drugs and Medical Devices (BfArM). The interim report including 327 patients was already published in the scientific journal LANCET EClinicalMedicine on May 2, 2021: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00163-2/fulltext
The report of the Crit-CoV-U study with 1,017 patients has been available to the BfArM and the Federal Ministry of Health (BMG) since mid-July. The DiaPat-CoV-50 test is now to be assessed as the only validated evidence-based test worldwide, proven in a prognostic study, for the early detection of the severe course of Covid-19 (from day "0" of the SARS-CoV2 Infection by means of PCR determination), finally to make it accessible to the legally insured via the remuneration of the statutory health insurance companies.
So far, this has been prevented with false information by the three impartial members of the G-BA and some health insurance companies, although the special approval of the test by the BfArM has been in place since December 2020 and the Crit-Cov-U study was accessible since March 1, 2021. The company regrets that due to false claims, many people suffered an unnecessary, avoidable, severe Covid-19 course and even died.